Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors

Journal of the National Cancer Institute

Volumn 92, Issue 1, 2000, Pages 48-53

  Radmacher, Michael D ^a,b   Simon, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ARTICLE; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CLINICAL TRIAL; COMPUTER SIMULATION; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; OCCULT CANCER; PRIORITY JOURNAL; STATISTICAL MODEL; TUMOR GROWTH;

EID: 0034606697     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.1.48     Document Type: Article

References (17)

1. Fisher B, Costantino JP, Wickerham DL. Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
2. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet 1985;1:836-40.
3. Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986;4:459-71.
4. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320: 479-84.
5. Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991;83:1299-306.
6. Wakeling AE, Valcaccia B, Newboult E, Green LR. Non-steroidal antioestrogens -receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem 1984; 20:111-20.
7. Bruzzi P. Tamoxifen for the prevention of breast cancer. Important questions remain unanswered, and existing trials should continue. BMJ 1988;316:1181-2.
8. Pritchard KI. Is tamoxifen effective in prevention of breast cancer? Lancet 1998;352: 80-1.
9. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352: 98-101.
10. Gallager HS, Martin JE. An orientation to the concept of minimal breast cancer. Cancer 1971;28:1505-7.
11. Heuser L, Spratt JS, Polk HC Jr. Growth rates of primary breast cancers. Cancer 1979;43: 1888-94.
12. Brown BW, Atkinson EN, Bartoszynski R, Thompson JR, Montague ED. Estimation of human tumor growth rate from distribution of tumor size at detection. J Natl Cancer Inst 1984;72:31-8.
13. Brown BW, Atkinson EN, Thompson JR, Montague ED. Lack of concordance of growth rates of primary and recurrent breast cancer. J Natl Cancer Inst 1987;78:425-35.
14. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988;48: 7067-71.
15. Shackney SE, McCormack GW, Cuchural GJ Jr. Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review. Ann Intern Med 1978;89: 107-21.
16. Steel GG. Growth kinetics of tumours. Oxford (U.K.): Oxford University Press; 1977, p. 31-3.
17. Moolgavkar SH, Day NE, Stevens RG. Two-stage model for carcinogenesis: epidemiology of breast cancer in females. J Natl Cancer Inst 1980;65:559-69.